Peptide Library

Human study PLS-00048

Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.

Case-control study · 400 participants enrolled · not included in the assessments (other)

Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

Only the abstract was available. Essential methods may be missing, which limits what can be judged.

Reports of this study

Every publication, registration and abstract describing this one study. Participants are counted once.

  • Circulating Mitochondrial Open Reading Frame of the 12S Ribosomal RNA Type-c Is Higher in Acute Coronary Syndrome and Is a Prognostic Biomarker for Major Cardiac Events in Patients With Acute Myocardial Infarction: A Case-Control Study.primary · Journal of the American Heart Association · 2025-12-10 · PMID 41368821 · DOI

Design and participants

Design
Case-control study
Population
Normal controls and patients with unstable angina or acute myocardial infarction, classified by clinical data and angiography
Conditions
Acute coronary syndrome, Unstable angina, Acute myocardial infarction
Setting
Hospital admission, with an 18-month follow-up for major adverse cardiac events
Planned enrollment (registry)
Not reported
Enrolled
400
Randomized
Not reported
Completed follow-up
Not reported
Funding
PubMed publication type indicates non-U.S. government research support; the funder is not named in the record
Authors’ conflicts
Not reported in the record

Intervention and comparator

What each group received. Related peptides, analogs and combinations are never treated as the compound itself.

    What the authors reported

    As stated in the sources. This is the authors’ account, not Peptide Library’s assessment.

    Adverse events

    None reported. That is not evidence of safety.

    Monitoring: Not applicable. No MOTS-c was administered to participants.

    The authors concluded (paraphrased): Higher circulating MOTS-c is associated with increased acute coronary syndrome risk. The imbalance between oxidative stress and circulating MOTS-c may help predict major adverse cardiac events after acute myocardial infarction.

    Peptide Library’s assessment

    An automated assessment, made by AI separately from the authors’ conclusions and not reviewed by a person. How risk of bias is assessed.

    Limitations

    • other: Endogenous serum MOTS-c was measured as a biomarker; the compound was never administered to participants.
    • abstract only: Only the abstract is available, and part of its results text appears truncated (the 'P P =0.003' fragment).
    • confounding: Observational case-control comparison of biomarker levels with no reported adjustment for confounders in the abstract.
    • inappropriate population: Participants had acute coronary syndrome or were controls, and endogenous MOTS-c was measured with no administration, so the study cannot show effects or safety of giving the compound.

    No risk-of-bias assessment has been published for this study’s results.

    Claims this study informs

    Where each value comes from

    • author_conclusion: PMID 41368821, abstract (Conclusions, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • design: PMID 41368821, title (title, 'A Case-Control Study') · extracted by AI (automated, not verified by a person) · abstract only
    • funding: PMID 41368821, citation (publication types) · extracted by AI (automated, not verified by a person) · abstract only
    • limitations: PMID 41368821, abstract (Methods, sentence 2; Results, sentence 3) · extracted by AI (automated, not verified by a person) · abstract only
    • participants: PMID 41368821, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only
    • population: PMID 41368821, abstract (Methods, sentence 1) · extracted by AI (automated, not verified by a person) · abstract only

    • Version 1 · published November 7, 2026 · evidence through November 7, 2026 · research snapshot 2026.1.1 · methodology ev-1 · Automated assessment by AI (claude-opus-5-5 and claude-sonnet-5-5), not reviewed by a person.

    These assessments describe published research. Records marked automated were produced by AI under the published methodology and have not been reviewed by a person; they can contain errors. None of this is medical advice, not a statement about any product’s safety for human use, and not a regulatory approval. Peptide Library’s vendor and partner relationships play no part in them (editorial independence).